Use of the Dietary Supplement 5-Aminiolevulinic Acid (5-ALA) and Its Relationship with Glucose Levels and Hemoglobin A1C among Individuals with Prediabetes
The study showed that 5-ALA is safe to administer at doses up to 50 mgs a day. Th is investigation showed a reduction in 2
5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects
Project Research Center for Clinical Trial and Preventive Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan Department of Molecular Microbiology and
Synergy of ferrous ion on 5-aminolevulinic acid-mediated growth inhibition of Plasmodium falciparum
Keisuke Komatsuya, Masayuki Hata, Emmanuel O. Balogun, Kenji Hikosaka, Shigeo Suzuki, Kiwamu Takahashi, Tohru Tanaka, Motowo Nakajima, Shun-Ichiro Ogura, Shigeharu Sato, Kiyoshi Kita Abstract Haem biosynthesis appeared to be a target of malaria therapy because
Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents
Naohide Yamashita, Atai Watanabe, Hikaru Kondo, Satofumi Kawata, Tohru Tanaka, Motowo Nakajima 5-ALA with SFC is a safe and potentially beneficial supplement if taken by
Registration of a U. S. Patent on a Method for Treating Diabetes Containing 5-ALA as an Active Ingredient
SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research
Notice of patent acquisition for diabetes treatment method using ALA as active ingredient in the United States
SBI Holdings Co., Ltd.SBI Pharma Co., Ltd. SBI Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative:), a subsidiary of SBI Holdings Co., Ltd., which conducts research
News Page – Disclaimer
The purpose of this page is to provide you an overview of the business in the industry & market information. Information in this page are derived from internal estimates, studies, researches conducted by third parties and general publications, as well as from sources that are considered reliable, by ABBACI Health (hereinafter referred to as “producers”). Industry publications, studies, and surveys usually indicate the data used are originated from sources that are considered reliable, but no guarantee upon the accuracy or completeness of such data. Producers believe these studies and publications are safe, but they have not independently verified the market and industry data from third-party sources. Similarly, producers think that their internal researches and information about the company is reliable, but not independently validated. Therefore, the content of this prospectus and its accuracy, including the realization or reasonableness of any forecasts, management estimates, prospects or returns, are not expressed or guaranteed by the producers.
The producer is not responsible for providing updates, corrections or other new data for any of the prospectus. This page contains forecasts, as well as potential future events, possible outcomes and projected growth (collectively referred to as “forward-looking statements” or “forward-looking projections”). Producers and their employees are not responsible for relying on or using the data of this page, or/and any liability of any nature to further convey the relevant data in writing or verbally. As this page is a confidential document, the content is strictly regulated and, without the express consent of the company or the producer, all or part of the data of this page may not be used, reproduced, transmitted, altered, published, stored, duplicated or otherwise used for any purpose.
This document is for informational purposes only and does not constitute an offer, advertisement or invitation to the public.
